Alto Neuroscience (ANRO) Invested Capital (2023 - 2026)

Alto Neuroscience has disclosed Invested Capital across 4 years of filings, most recently posting $245.4 million for Q1 2026.

• Invested Capital for Q1 2026 came in at $245.4 million, up 74.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $245.4 million (up 74.83% YoY), and the FY2025 annual result was $153.1 million, down 5.3% from the prior year.
• Invested Capital came in at $245.4 million for Q1 2026 at Alto Neuroscience, up from $153.1 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $245.4 million in Q1 2026 to a low of -$71.7 million in Q4 2023.
• The 4-year median for Invested Capital is $140.3 million (2025), against an average of $98.2 million.
• Across the five-year window, Invested Capital soared 549.01% in 2024 and sank 35.19% in 2025, its largest moves.
• Alto Neuroscience's Invested Capital stood at -$71.7 million in 2023, then jumped by 325.63% to $161.7 million in 2024, then decreased by 5.3% to $153.1 million in 2025, then soared by 60.22% to $245.4 million in 2026.
• The last three Invested Capital figures came in at $245.4 million (Q1 2026), $153.1 million (Q4 2025), and $113.6 million (Q3 2025), per Business Quant data.